The protein may be a therapeutic or diagnostic protein.

Fusion protein comprising a protein to be fused, e.g. a therapeutic protein fused to the C-terminal of osteogenic growth peptide (OGP).

The transferred DNA may include any DNA encoding a therapeutic protein of interest.

In some embodiments, the therapeutic protein is antithrombin.

The invention is a method of administering a therapeutic protein to a mammal by introducing into the omentum of the mammal a cell genetically engineered to secrete the therapeutic protein.

The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target.

The stabilizing agent will protect the therapeutic protein during the encapsulation process and inhibit proteolytic enzymes in the small intestines thereby allowing the therapeutic protein to reach lymphoid tissue in the small intestines.

For example, the therapeutic protein can be a bone morphogenic protein when the tissue to be treated is bone tissue.

Methods and compositions of the invention involve associating an IGF moiety with a therapeutic protein in order to target the therapeutic protein to the brain.

The transfected cancer cells are genetically modified to express one or more therapeutic proteins.

The modulator maybe a small chemical molecule, antibody or other therapeutic protein.

USP<787> Subvisible particulate matter in therapeutic protein injections

Provided herein are integrated continuous biomanufacturing processes for producing a therapeutic protein drug substance.

The recombinant organisms expressing a therapeutic protein can also be used to treat a disease or undesirable condition which is characterized by a deficiency in that protein.

USP<787> Subvisible particulate matter in therapeutic protein injections